Naloxone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Naloxone: From Opioid Overdose Reversal to Continuous Spikes and Waves During Sleep
One-Sentence Summary
Naloxone is a competitive opioid receptor antagonist most widely known for reversing opioid overdose and opioid-induced respiratory depression. The TxGNN model’s top prediction for this drug is continuous spikes and waves during sleep (CSWS), a rare paediatric epileptic encephalopathy, but this direction is currently supported by 0 clinical trials and 0 publications. This is a model-only signal with no corroborating clinical or mechanistic evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this evidence pack’s regulatory data (no ARTG licences found); naloxone is generally used to reverse opioid overdose/respiratory depression |
| Predicted New Indication | Continuous spikes and waves during sleep (CSWS) |
| TxGNN Prediction Score | 88.17% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for this candidate was not available in the evidence pack (DrugBank MOA field flagged as a data gap). Based on general pharmacological knowledge, naloxone is a competitive antagonist at opioid receptors (predominantly mu-opioid), and its established clinical role is reversing the effects of opioid agonists in overdose or perioperative settings.
CSWS is a rare, structurally and electrophysiologically defined childhood epilepsy syndrome. There is no established pathophysiological link between opioid receptor blockade and the mechanisms thought to drive CSWS (abnormal cortico-thalamic synchronisation during sleep). No clinical trials or publications were retrieved connecting naloxone (or related opioid antagonists) to this condition, so the prediction currently rests entirely on TxGNN’s embedding-based similarity score, with no independent evidence to support or refute a plausible mechanistic rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
No ARTG entries were identified for naloxone in this evidence pack, and market status is recorded as not marketed. This should be independently confirmed against the current TGA/ARTG database, as naloxone products are generally available in other markets for opioid overdose reversal — the absence of a record here may reflect a data-collection gap rather than true non-availability.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. Key warnings, contraindications, and drug interaction data were not available in this evidence pack (DDI query returned no results).
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (CSWS) has no supporting clinical trials or literature (L5 — model prediction only) and no plausible mechanistic link between opioid receptor antagonism and this rare paediatric epilepsy syndrome. In addition, a blocking data gap on TFDA/TGA warnings and contraindications currently prevents even an initial safety screen (S1) for naloxone in this evidence pack.
To proceed, the following is needed:
- TGA-approved Product Information (warnings, contraindications, interactions) to clear the blocking safety gap
- Confirmed DrugBank/mechanism-of-action detail for naloxone
- Confirmation of current ARTG/marketing status in Australia
- Any emerging clinical or preclinical evidence directly linking opioid antagonism to CSWS before this candidate is reconsidered
Note: Other TxGNN-ranked candidates for naloxone (e.g., psychotic disorder, schizophreniform disorder) have somewhat more evidence volume but suffer from drug-identity mismatch — most retrieved trials/literature involve naltrexone rather than naloxone itself — and were independently scored Hold. None currently clear the bar for further progression.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.